Hey,
We have released new coverage of stem cell markets that I am excited to share with you. Let me know what you think?
Don’t Get Swept Away By the Hype Surrounding “Unregulated” Stem Cell Clinics (Regulated Companies Exist Too)Recently, a great deal of negative press has been given to stem cell clinics, with prominent media outlets announcing that “Warning Letters” have been mailed to hundreds of stem cell clinics across the United States. What this fear-based hype does not tend to highlight is the promising regenerative medicine potential associated with autologous stem cell therapies. Additionally, the hype surrounding “unregulated” stem cell clinics does not give proper credit to the companies cooperating with regulatory bodies to ensure a safe and efficacious patient experience.
Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced that the first patient with sickle cell disease (SCD) has been transplanted with CordIn™. CordIn is an experimental curative treatment for rare non-malignant diseases where bone marrow transplantation is the only currently available cure. CordIn™, NiCord®, and other products under development by Gamida Cell, all utilize the company’s proprietary NAM platform technology to expand cells while preserving and enhancing their functionality.
Two-Thirds of All Mesenchymal Stem Cell (MSC) Publications Were Released in the Past 5 Years
Wow, a search of the PubMed database for scientific publications containing the term “mesenchymal stem cell” or “mesenchymal stem cells” now returns nearly 30,000 results – 28,597 to be exact. Additionally, mesenchymal stem cell (MSC) scientific publications have increased in number every year since 1992. That is 26 years in a row. If those numbers haven’t shocked you, then this will. 17,804 of those MSC articles were released in the last 5 years (62%).
Cell Symposium's "10 Years of iPSCs" to Explore New Ideas and Future Growth, as iPSC Field Enters Second DecadeLeaders from biology, medicine, and industry will convene in California on September 25-27th to mark a decade of iPSCs, the Nobel Prize winning discovery reported by Shinya Yamanaka and Kazutoshi Takahashi in Cell in 2006. Hear an up-to-date view of this rapidly moving area, including presentations spanning the latest advances in technology development through to the therapeutic application of reprogramming for drug development and cell-based therapy. The goal of the meeting is to serve as a catalyst for new ideas and future growth, as the iPSC and reprogramming field enters its second decade.
WideCells Group PLC, a Global Stem Cell Services Company, Goes Public with £2m IPOWideCells Group, the health care services company focused on collecting and storing stem cells and providing ground breaking insurance for stem cell treatment, announced that it has been admitted to trading on the London Stock Exchange. Funds raised are intended to build an integrated stem cell services company, focused on promoting stem cell treatments by making them accessible and affordable
Axiogenesis is hosting a Human iPSC Applications Workshop in Cologne, Germany on September 7 – 9, 2016. Attend this event to learn how experts in the pharmaceutical industry and leading academic institutions are using Axiogenesis’ cells and assays in drug discovery, safety/toxicology screening, and bioengeneering, as well as to understand current approaches to establishing and defining standards for these cellular models. Axiogenesis has successfully staged user meetings since 2014, which represent an opportunity to get insights into iPSC applications and network.
This global strategic report evaluates strategies across the entire stem cell product spectrum. It explores unique market opportunities by stem cell type, including mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs), induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs), neural stem cells (NSCs), and more. Remember, you level of income will rarely exceed your level of knowledge. Invest in yourself and your company - or your competitors will.
Be Great!
Cade President/CEO of BioInformant.com "1st and Only Market Research Firm to Specialize in the Stem Cell Industry"
p.s. Have an important stem cell announcement to share? Hit "reply" to this email to reach me.
|
|
|
